Evidence map›Paper›PMID 29768470›Full record

ArticlePloS one2018

Integrative omics to detect bacteremia in patients with febrile neutropenia.

Rachel S Kelly, Jessica Lasky-Su, Sai-Ching J Yeung, Richard M Stone, Jeffrey M Caterino, Sean C Hagan, Gary H Lyman, Lindsey R Baden, Brett E Glotzbecker, Christopher J Coyne and 2 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Article
  7. Metabolites and Cognitive Decline in a Puerto Rican Cohort.Journal of Alzheimer's disease : JAD · 2024
    Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 1 country.

Rachel S KellyChanning Division of Network Medicine, Brigham and Women's Hospital, Boston, MA, United States of America.
Jessica Lasky-SuChanning Division of Network Medicine, Brigham and Women's Hospital, Boston, MA, United States of America.
Sai-Ching J YeungDepartment of Emergency Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States of America.
Richard M StoneHarvard Medical School, Boston, MA, United States of America.
Jeffrey M CaterinoOhio State University Medical School, Wexner Medical Center Department of Emergency Medicine, Columbus, OH, United States of America.
Sean C HaganDepartment of Emergency Medicine, Brigham and Women's Hospital, Boston, MA, United States of America.
Gary H LymanFred Hutchinson Cancer Research Center, Seattle, WA, United States of America.
Lindsey R BadenHarvard Medical School, Boston, MA, United States of America.
Brett E GlotzbeckerHarvard Medical School, Boston, MA, United States of America.
Christopher J CoyneUniversity of California, San Diego, School of Medicine and Department of Emergency Medicine, San Diego, CA, United States of America.
Christopher W BaughHarvard Medical School, Boston, MA, United States of America.
Daniel J PallinHarvard Medical School, Boston, MA, United States of America.ORCID 0000-0002-8517-9702
Brigham and Women's Hospital · USHarvard University · USThe Ohio State University Wexner Medical Center · USThe University of Texas MD Anderson Cancer Center · USUniversity of California San Diego · USUniversity of Washington · US

Funding

Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Jennifer A. Woyach · 1985 to 2026
$132.3M
TYROSINE KINASE ONCOGENESIS IN MYELOID LEUKEMIAP01CA066996 · NCI · DANA-FARBER CANCER INSTITUTE · PI SCOTT A ARMSTRONG · 1996 to 2026
$52.5M
Integrative Metabolomics of Asthma SeverityR01HL123915 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI LASKY-SU, JESSICA A · 2014 to 2023
$7.0M
NCI NIH HHS P01 CA066996NCI NIH HHS P30 CA016058NHLBI NIH HHS R01 HL123915NIH HHS 1R01HL123915-01
6 · The paper itself

Abstract

backgroundCancer chemotherapy-associated febrile neutropenia (FN) is a common condition that is deadly when bacteremia is present. Detection of bacteremia depends on culture, which takes days, and no accurate predictive tools applicable to the initial evaluation are available. We utilized metabolomics and transcriptomics to develop multivariable predictors of bacteremia among FN patients.

methodsWe classified emergency department patients with FN and no apparent infection at presentation as bacteremic (cases) or not (controls), according to blood culture results. We assessed relative metabolite abundance in plasma, and relative expression of 2,560 immunology and cancer-related genes in whole blood. We used logistic regression to identify multivariable predictors of bacteremia, and report test characteristics of the derived predictors.

resultsFor metabolomics, 14 bacteremic cases and 25 non-bacteremic controls were available for analysis; for transcriptomics we had 7 and 22 respectively. A 5-predictor metabolomic model had an area under the receiver operating characteristic curve of 0.991 (95%CI: 0.972,1.000), 100% sensitivity, and 96% specificity for identifying bacteremia. Pregnenolone steroids were more abundant in cases and carnitine metabolites were more abundant in controls. A 3-predictor gene expression model had corresponding results of 0.961 (95%CI: 0.896,1.000), 100%, and 86%. Genes involved in innate immunity were differentially expressed.

conclusionsClassifiers derived from metabolomic and gene expression data hold promise as objective and accurate predictors of bacteremia among FN patients without apparent infection at presentation, and can provide insights into the underlying biology. Our findings should be considered illustrative, but may lay the groundwork for future biomarker development.

Indexed as

BacteremiaChemotherapy-Induced Febrile NeutropeniaMetabolomeMetabolomicsNeoplasmsAdultFemaleGene Expression Regulation, NeoplasticHumansImmunity, InnateMaleMiddle Aged

Identifiers

PMID29768470
PMCPMC5955575
OpenAlexW2804739798

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.